Overview: CD34 Immunohistochemistry TestIntroduction: The CD34 Immunohistochemistry Test detects CD34 protein to diagnose vascular tumors or leukemia, causing lumps or fatigue. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected vascular tumors or leukemias.
Other Names: CD34 IHC Assay, Vascular Tumor/Leukemia IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD34 testing began in the 1990s with hematopoietic and vascular research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD34 to diagnose vascular tumors or leukemia, guides treatment, and evaluates patients with lumps or fatigue.
Test Parameters: 1. CD34 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or bone marrow aspiration. Report history of lumps, fatigue, or leukemia symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lumps, fatigue, bleeding, or family history of vascular tumors or leukemia. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or aspiration.
Procedural Considerations: Uses immunohistochemistry to detect CD34 in tissue or bone marrow. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for vascular tumor or leukemia diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD34 staining suggests vascular tumors (e.g., angiosarcoma) or leukemia, guiding chemotherapy or surgery. Negative staining may require further marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD31 IHC, FLT3 mutation testing, or bone marrow biopsy to confirm vascular tumor or leukemia diagnosis.
Test Limitations: Not specific to one condition; other tumors may express CD34. Clinical correlation is needed.
References: WHO Hematopathology Guidelines, 2023; Blood, Arber DA, 2022.
